The 5 Most Interesting Analyst Questions From Waters Corporation’s Q2 Earnings Call

Waters Corporation’s Q2 results were met with a positive market reaction, driven by strong organic growth and momentum from its recently acquired Biosciences and Diagnostic Solutions businesses. Management pointed to robust demand across pharmaceutical, academic, and government markets, as well as the successful integration of new product launches. CEO Udit Batra highlighted that, "GLP-1 testing part of the business grew over 40% this quarter," with broad-based contributions across regions. The